Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

316
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
316

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT.

Bone marrow transplantation·2026
Same author

Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee.

Bone marrow transplantation·2026
Same author

Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology.

Leukemia·2026
Same author

Measurable residual disease is not a universally reliable surrogate for progression-free survival in clinical trials of new chronic lymphocytic leukemia therapies.

Leukemia·2026
Same author

Redefining light-chain smoldering multiple myeloma: prevalence and progression risk.

Leukemia·2026

Related Experiment Video

Updated: Jun 14, 2025

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.7K

End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.

Florian Simon1, Rudy Ligtvoet1, Sandra Robrecht1

  • 1Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf; German CLL Study Group, University of Cologne, Cologne, Germany.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|August 30, 2024
PubMed
Summary

Progression-free survival (PFS) and minimal residual disease (MRD) show strong patient-level correlation with overall survival (OS) in chronic lymphocytic leukemia (CLL) targeted therapy trials. Treatment-effect correlation between PFS and OS remains uncertain, though MRD correlates well with PFS.

More Related Videos

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.4K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.0K

Related Experiment Videos

Last Updated: Jun 14, 2025

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.7K
Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.4K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.0K

Area of Science:

  • Oncology
  • Clinical Trials
  • Hematology

Background:

  • Surrogate endpoints like progression-free survival (PFS) and minimal residual disease (MRD) are crucial for estimating treatment efficacy in chronic lymphocytic leukemia (CLL) studies.
  • Understanding the correlation between these surrogate endpoints and overall survival (OS) is vital for advancing CLL therapies.

Purpose of the Study:

  • To analyze the patient-level and trial-level correlation between PFS and MRD with OS in first-line CLL trials.
  • To validate these correlations in the context of targeted therapies (TT) versus chemotherapy/chemoimmunotherapy (C/CIT).

Main Methods:

  • Patient-level correlation was assessed using data from 4,237 patients in German CLL Study Group (GCLLSG) trials.
  • A joint-frailty copula model was employed to validate correlations, particularly for TT.
  • A meta-analysis of 16 first-line phase III CLL trials (2008-2024) involving 8,065 patients was conducted to quantify treatment-effect correlation.

Main Results:

  • Patient-level correlation between PFS and OS was strong (Spearman Rho >0.9).
  • Treatment-effect correlation between PFS and OS was moderate (R=0.75) for C/CIT and strong for TT (tau=0.91).
  • End-of-treatment MRD showed a strong correlation with PFS (R=0.88) but a weaker correlation with OS (R=0.71).

Conclusions:

  • Patient-level correlation between PFS and OS is confirmed for TT in CLL.
  • Treatment-effect correlation between PFS and OS requires further investigation.
  • MRD response strongly correlates with PFS but not consistently with OS, highlighting the need for more randomized trials with MRD data.